Evidence map›Paper›PMID 29744080›Full record

ArticleClinical case reports2018

Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously.

MSoledad Noya, Marcio Andrade-Campos, Pilar Irun, Laura López de Frutos, MFernanda López-Fernandez, Pilar Giraldo

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

MSoledad NoyaDepartment of Hematology CHUAC A Coruña Spain.
Marcio Andrade-CamposTranslational Research Unit Miguel Servet University Hospital IIS-Aragon Zaragoza Spain.
Pilar IrunTranslational Research Unit Miguel Servet University Hospital IIS-Aragon Zaragoza Spain.
Laura López de FrutosTranslational Research Unit Miguel Servet University Hospital IIS-Aragon Zaragoza Spain.
MFernanda López-FernandezDepartment of Hematology CHUAC A Coruña Spain.
Pilar GiraldoTranslational Research Unit Miguel Servet University Hospital IIS-Aragon Zaragoza Spain.ORCID 0000-0002-8791-1901
Centre for Biomedical Network Research on Rare Diseases · ESComplexo Hospitalario Universitario A Coruña · ESHospital Universitario Miguel Servet · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Report a female diagnosed as type 1 Gaucher disease after a femoral pathologic fracture when she was 55 years old. Enzyme replacement therapy was started, and she achieved therapeutic goals. In 2015, a Ph' CML with numerous pseudo-Gaucher cells in bone marrow appears. BCR/ABL was not present at GD diagnosis.

Indexed as

Chronic myeloid leukemiaenzymatic replacement therapyGaucher diseasetyrosine kinase inhibitors

Identifiers

PMID29744080
PMCPMC5930224
OpenAlexW2790477731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.